MONOCLONAL ANTIBODIES - A NEW HOPE IN COVID-19 TREATMENT - UK-based pharmaceutical company  AstraZeneca  announced on Tuesday that it had begun the human trial of a new treatment for  Covid-19  using a combination of two monoclonal antibodies. "The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of Covid-19," the multinational giant said in a press release Up to 48 healthy people aged 18 to 55 years will take part in the first stage of the trial, aimed at evaluating the safety, tolerability and pharmacokinetics of the new treatment, the company added. "This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance," Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said in the statement. If the treatment is successful, AstraZeneca said it would then move into larger late-stage Phase II and Phase III trials to evaluate its efficacy as a potential preventative and treatment approach against Covid-19. The scientific study is funded by the US Defence Advanced Research Projects Agency, which is part of the US Department of Defence and the Biomedical Advanced Research and Development Authority, attached to the US Department of Health and Human Services.



We all are glewed to such studies and eagerly waiting but as we know nothing can be materialised so soon It will take its due time I hope by the time we all will be having enough HERD immunity

Thank you doctor

View 2 other replies

Information is good The world is coming together to fight Covid and the research is at its best

Thank you doctor

Nice post interesting

Thank you doctor

Informative post Sir

Nice informative post

Bharat Bio-Tech is also planning to manufacture monoclonal antibodies for covid19 infection


Valuable information Sir.

Nice one

Diseases Related to Discussion


Cases that would interest you